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Background:  Opioid  substitution  treatment  (OST)  has  been  implemented  in Taiwan  since  2006.  We  esti-
mated  the  life  expectancy  (LE)  and  expected  years  of life  lost  (EYLL)  in a cohort  of heroin  users  stratiﬁed
by  OST  for  comparison.
Methods: A  total  of  1283  heroin  users  recruited  from  2006  to  2008  were  linked  to  the National  Mor-
tality  Registry  until  the  end of 2011.  Among  them,  983  received  OST,  while  300  did not.  Kaplan–Meier
estimation  for  survival  was performed,  and  it was  extrapolated  to 50  years  to obtain  the  LE using a  semi-
parametric  method.  We  further  estimated  the EYLL  for both  cohorts  by  subtracting  their  life  expectancies
from  the  age-  and  sex-matched  referents  of  the  general  population.  Cause-speciﬁc  standardized  mortality
ratios (SMRs)  were  calculated  and  compared  with  the  national  cohort  to validate  the  representativeness
of  this  sample.
Results: After  extrapolation  to  50  years  of survival,  the  estimated  average  LE  and  EYLL  were  27.4 and
10.6  for  OST  subjects,  respectively,  while  those  of  the  non-OST  were 20.2  and  18.4  years.  The  all-cause
mortality  rates  (per  1000  person-years)  in  the  observational  period  for the  OST  and non-OST  group were
15.5  and  23.9,  respectively,  representing  a 7.5- and  10.2-fold  SMR  compared  to  the  general  population,
indicating  a high  representativeness  for our sample.  But  SMR  of  suicide  mortality  elevated  16.2  and  3.1
folds in  OST  and  non-OST  group,  respectively.
Conclusions:  OST  saves  7.8  EYLL  more  than  non-OST  after  accounting  for  lead  time  bias.  Effective  sui-
cide  prevention  programs  could  enhance  its  life-saving  effect,  especially  among  those  co-morbid  with
depressive  disorders.
©  2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC. IntroductionIllicit opioid use contributes to a heavy burden of disease
lobally (Degenhardt et al., 2013), and mortality rates have been
eported to be as high as six to thirty times that of the general
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population (Darke et al., 2007). This excess mortality is concen-
trated across several causes of death: drug overdose, trauma,
including suicide and homicide, and somatic causes, including
blood-borne infection (Clausen et al., 2009). It should be noted
that geographic differences have been evident, and mortality rates
appear to be the highest in Asia (Degenhardt et al., 2011). Despite
the fact that life expectancy (LE) and/or years of potential life lost
(YPLL) for heroin cohorts have been reported (Smyth et al., 2006;
Degenhardt et al., 2014), a follow-up study regarding this important
issue in Asia seems to be lacking.
The opioid substitution treatment (OST), a long-term pharmaco-
logical maintenance on methadone and buprenorphine for opioid
dependence, has received wide attention because of its effect to
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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educe excess mortality risks (Degenhardt et al., 2009; Cornish
t al., 2010; Kimber et al., 2010). However, the life-saving effect of
ST is salient only while heroin users remained under treatment,
nd many OST participants are exposed to an elevated overdose risk
fter treatment cessation and during the induction to methadone
reatment (Brugal et al., 2005; Degenhardt et al., 2009; Cornish
t al., 2010; Degenhardt et al., 2011). Although Bell et al. (2009) have
hown that heroin users entering buprenorphine treatment have
ower mortality risk during induction, the long-term survival for
hese two agents did not appear to be quite different (Degenhardt
t al., 2009; Gibson et al., 2008). In addition, few existing exami-
ations have had sufﬁcient power to examine mortality between
eroin users seeking OST and those who do not.
Taiwan adopted an OST (commonly oral methadone) program in
esponse to the HIV epidemic in 2006 (Chen and Kuo, 2007). There-
fter, mortality studies on heroin cohorts have reported ﬁndings
etween 2006 and 2008 (Huang et al., 2011; Huang and Lee, 2013;
ee et al., 2013; Liao et al., 2013). Huang et al. (2011) have shown
hat continued participation in OST is associated with substantial
ower mortality among ex-prisoners. One hospital-based study has
eported that older age, HIV infection, psychiatric treatment his-
ory and alcohol use disorders are risk factors for mortality (Huang
nd Lee, 2013). Studies employed nationwide registry data showed
o signiﬁcantly increased overdose mortality during the induction
r rapid titration of methadone treatment (Huang et al., 2011; Liao
t al., 2013). Moreover, Lee et al. (2013) detected a high risk of pre-
ature death through suicide. However, the expected years of life
ost (EYLL) for a heroin cohort has not yet been investigated.
Because many heroin cohorts may  not have been followed for
 sufﬁcient amount of time, we used a semiparametric method for
ifetime extrapolation (Hwang and Wang, 1999). By recruiting a
eroin cohort stratiﬁed by OST for comparison, we  attempted to
etermine the LE and EYLL of both OST and untreated subjects. In
ddition, we also examined the standardized mortality ratio (SMR)
o evaluate the representativeness of our cohort.
. Methods
This study commenced after the approval of the Institutional Review Board of
he Jianan Psychiatric Center, MOHW (JMH08033 and JMH12050)
.1. Data sources
In the beginning of 2006, the Taiwan Center for Disease Control (CDC) pro-
osed a pilot methadone maintenance treatment (MMT)  program in four of Taiwan’s
3  administrative regions (three in northern Taiwan and in the Jianan Psychiatric
enter in the south). In addition to existing detoxiﬁcation and drug-free psychoso-
ial programs, as well as the new MMT  program, the Taiwan CDC also permitted
uprenorphine (Suboxone) to be used as a substitution treatment as a pilot study
eginning in 2006. Among different hospitals, the Jianan Psychiatric Center was the
nly pilot OST program institution providing both oral methadone and sublingual
uprenorphine. We  conducted an observational cohort study by recruiting heroin
sers into the study and OST ﬁrst, which were linked to the National Mortality Reg-
stry  to determine if the subject was deceased and the cause of mortality. The SMRs
standardized mortality ratios) were then calculated and compared with those of
inkage between the National OST system and National Mortality Registry to assure
he  representativeness of our cohort.
All subjects included in this study were diagnosed with opioid dependence by
ualiﬁed psychiatrists from the Jianan Psychiatric Center research team from March,
006 to July, 2008. The inclusion criteria were: (1) being more than 20 years old; (2)
eeting the DSM-IV (Fourth edition of Diagnostic and Statistical Manual of Mental
isorders) criteria for opioid dependence; (3) no other OST contraindication, such
s severe liver cirrhosis. The cohort was comprised of 1609 participants, of whom
83 voluntarily joined our OST programs during the recruitment period. Of the total
f  983 subjects registered in the OST program, about one-tenth (94/983) received
uprenorphine treatment, while all the others received methadone. To minimize
nancial burden, Taiwan CDC stipulates that any subject originally randomized to
eceive buprenorphine in a pilot study be shifted into methadone treatment if he/she
annot adhere to the medication schedule. At the end of the 2011, 92 subjects shifted
o  methadone maintenance treatment.
The National OST system was managed and maintained by the Taiwan CDC.
t  was established after OST programs began in 2006. All clinics and hospitals areependence 153 (2015) 152–158 153
required to provide information on every methadone or publically funded buprenor-
phine patient, including the date of prescription, dose, quantity, and record of daily
attendance. Of the remaining 626 participants, we deﬁned 300 subjects as the
untreated (non-OST) group after veriﬁcation with the national registry of the OST
system during the 70 months of follow-up after the ﬁrst evaluation. The other 326
were excluded because they were later enrolled into OST programs sometime in our
studying period. In fact, these subjects shifted back and forth frequently between
the two  groups and we have decided to exclude them to avoid confounding in the
end.
Almost all OST participants received blood tests for HIV, HCV, HBV and syphilis,
while 287 out of 300 non-OST heroin users received blood test for HIV. Only about
170 non-OST heroin users completed blood tests for HCV, HBV and syphilis and there
was no signiﬁcant difference with regard to demographic and clinical characteristics
stratiﬁed by those received blood test or not.
2.2. Cause of death
Deaths in our study cohort were identiﬁed by the patient’s chart or by record
linkage with the National Death Certiﬁcation Registry system, which is regularly
managed by the Taiwan’s Ministry of Health and Welfare and contains all informa-
tion reported in the death certiﬁcates, including name, identiﬁcation number (ID),
date of birth, sex, date of death and the cause of death. Deaths were coded using the
International Classiﬁcation of Disease, Ninth Revision (ICD-9) (2006–2008) or Inter-
national Classiﬁcation of Disease, Tenth Revision (ICD-10) (2009–2011). In addition,
we  conducted telephone interviews with a key person related to the deceased to
explore relevant information on the cause of death, opioid or other substance use
behaviors, and related physical condition.
2.3. Statistical analysis
We were able to follow this cohort and applied the Kaplan–Meier method to
estimate survival function based on the follow-up data from 2006 to 2011. Person
years of follow-up were calculated from baseline interview date until date of death
or  censored on December 31, 2011. Crude mortality rates per 1000 person years (PY)
with 95% conﬁdence intervals (CIs) were calculated. Standardized mortality ratios
(SMRs) were calculated as the observed number of deaths divided by the expected
number of deaths, with age-, sex-, year-, and cause-speciﬁc mortality rates in the
Taiwan population used to calculate the expected number of deaths.
2.4. Extrapolation of long-term survival for the OST and non-OST cohort
Heroin users usually would die of mortality causes that are directly related to this
illness, such as suicide and trauma, in addition to the common causes experienced by
age- and sex-matched general population. Assuming that such additional mortality
would become stable, or, that constant excess hazard exists after several years of
follow-up, we can apply an extrapolation method to quantify their lifetime survival
function by borrowing information from general population or life tables of national
vital statistics (Hwang and Wang, 1999; Fang et al., 2007).
The method was composed of three processes (Hwang and Wang, 1999), brieﬂy
summarized as follows: for every individual in the OST or non-OST cohort, we ﬁrst
created an age- and sex-matched referent from the life tables of the general pop-
ulation using the Monte Carlo method. The life tables for the general population
were obtained directly from the national vital statistics published by the Depart-
ment of Statistics, Ministry of the Interior, Executive Yuan, Taiwan. The survival
curve for the cohort of age- and sex-matched referents was obtained by applying
the Kaplan–Meier method. Second, we ﬁtted a simple linear regression line to the
logit  of the ratio of survival functions between the OST  (or non-OST) and referent
cohorts to the end of the follow-up. Finally, the regression line and survival curve
for the cohort of referents were used to predict a long-term survival curve beyond
the  follow-up for this cohort. We extrapolate the unﬁnished survival curves up to
50  years to account for the usual life expectancy of general population with a similar
age.
The standard errors of the means were also calculated by the bootstrap method
for 100 repeated samples in these parameters, as stratiﬁed by OST or not. To facili-
tate the computation, we used the ISQoL (integration of survival and quality of life)
software program, which can be freely downloaded from http://www.stat.sinica.
edu.tw/isqol/. Detailed methods and mathematical proofs are described in the pre-
vious studies (Chu et al., 2008; Fang et al., 2007; Hung et al., 2014; Hwang and Wang,
1999; Liu et al., 2013). We provide technical material as a supplement.
2.5. Estimation of EYLL
Subsequently, the LE and EYLL in both the OST and non-OST group were esti-
mated and potential LY saved by the effect of OST were calculated. The average EYLL
of  the OST (or non-OST) cohort was estimated as the difference in the area between
the  mean survival curves of the OST (or non-OST) cohort and the reference pop-
ulation. This calculation provides a measure of the burden of opioid dependence
on  an individual and yields an estimation of how much an individual’s life is likely
to be shortened by opioid dependence. It could also represent the amount of an
individual’s life that is likely to be saved by treatment.
1 ohol Dependence 153 (2015) 152–158
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Fig. 1. Mean survival difference between heroin users and age- and sex-matched
reference population after 50 years of extrapolation. (a) OST (opioid substitution
treatment) group and (b) non-OST group.
Fig. 2. Logit transformation of the survival ratio W(t) of the survival functions of
heroin users and that of the age- and gender-matched reference population gen-
erated by the Monte Carlo method. The solid line is the linear regression line. The54 K.-C. Chang et al. / Drug and Alc
. Results
.1. Characteristics of the cohort
A total of 1283 individuals were included during the recruit-
ent period, among whom 983 were enrolled in OST (OST group),
nd 300 were not (non-OST group, never registered for OST dur-
ng 2006–2011). Table 1 summarizes the baseline characteristics
etween these two groups. Overall, the mean age was  37.5 ± 8.8
ears, about half of them were employed (55.7%) and single (49.5%),
nd most were male (87.8%). OST subjects reported a lower propor-
ion of family bonding than the non-OST (66.7% vs. 90.8%, p < 0.001).
he proportion of the OST group with an educational level above 9
ears was signiﬁcantly lower than that of the non-OST group (33.6%
s. 47.3%, p < 0.01). The mean age at the time of beginning heroin
se was 26.0 ± 6.6 years. The proportion of injective drug users
IDUs) for the OST group was higher than that of the non-OST group
91.0% vs. 84.5%, p = 0.0016). The IDUs enrolled in OST reported a
igher proportion of ever needle or syringe sharing (78.3% vs. 40.8%,
 < 0.001). Approximately seventy percent of our sample reported
mphetamine abuse. The overall prevalence rate of current alcohol
se disorder was 22.7%, but did not differ between the two groups
Table 1). The OST group also had a signiﬁcantly higher HIV (18.1%
s. 6.3%, p < 0.001) and HCV infections (91.4% vs. 86.4%, p = 0.0378).
.2. Mortality and comparison with the general population
The sum of all of the years followed for each person was  5819
erson-years (PY). A total of 102 deaths (8%) occurred by the end
f the follow-up. The crude mortality rate among OST patients
as lower than that in the non-OST group (15.5 vs. 23.9 per 1000
erson-year), as summarized in Table 2. The SMR’s of all causes and
xternal causes were higher in the non-OST group as compared to
hose in the OST group (Table 2). The observed difference in SMR
as especially large in causes of drug overdose (126.1 vs. 482.4
or OST vs. non-OST). Conversely, suicide mortality rate among
ST group was much higher than non-OST group (mortality rates
deaths per 1000 person-years (pys)]: 3.9 vs. 0.7, p < 0.001). After
djustment for age-, sex- and calendar-year, the SMR  for suicide
n OST heroin users was 16.2, which was substantially higher than
hat of the non-OST group (SMR for suicide = 3.1), and the OST group
articipants were more likely to die of infectious diseases than was
he case for those in the non-OST group, with an SMR  of 25.0 vs.
.9. The SMR  for neoplasms was also higher (3.6 vs. 5.5 for OST vs.
on-OST), while deaths from liver disease and hepatitis, while also
igher, had relatively lower SMR’s, 4.1 and 3.4 for OST and non-OST,
espectively.
.3. LE and EYLL
The 6-year follow-up data were used to extrapolate the lifetime
urvival time up to the 50th year after diagnosis for the estima-
ion of the LE, which were 27.4 and 20.2 years after diagnosis,
espectively, for the OST and non-OST heroin users, as depicted
n Fig. 1a and b. Compared with the sex- and age-matched refer-
nts, the EYLLs were 10.6 and 18.4 for the OST and non-OST heroin
sers, respectively. After adjustment for age and sex, the non-OST
roup exhibited an additional loss of 7.8 life-years (=18.4–10.6)
n comparison with the OST group. Namely, OST saves lives after
aking into account lead time bias. Because our method of extrapo-
ation is valid if constant excess hazard can be assumed (Fang et al.,
007; Andersson et al., 2013), we provide Fig. 2a and b, for OST and
on-OST, respectively, as the evidence of proof of validity for our
stimates. Namely, the slope of logit transform of survival ratio is
stimable for both cohorts.
vertical dotted line marks the time period when the data were used for extrapola-
tion, while the horizontal dotted line indicates the slope of logit survival ratio. When
the curve of logit survival ratio converges to a stable straight line and its slope is
estimable, it means that the assumption of constant excess hazard is fulﬁlled for
both (a) OST (opiate substitution treatment) group and (b) non-OST group.
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Table  1
Comparisons of demographics and clinical features of the cohorts and stratiﬁed by opioid substitution treatment (OST).
Characteristics OST group Non-OST group P value
No. % No. %
Total 983 100.0 300 100.0
Demographics
Sex  0.3613
Male  868 88.3 259 86.3
Female 115 11.7 41 13.7
Age  (mean ± SD)* 37.8 ± 7.7 36.6 ± 11.7 0.0425
20–34  364 37.0 151 50.3
35–49 542 55.1 127 42.3
≥50 77 7.8 22 7.3
Education** <0.001
≤6  years 118 12.0 74 24.7
7–9  years 533 54.3 84 28.0
≥10 years 330 33.6 142 47.3
Marital status 0.1500
Single 473 48.3 157 53.6
Divorced or separated 233 23.8 55 18.8
Married 274 28.0 81 27.7
Dropout in school (yes)** 291 32.5 32 17.3 <0.001
Family bonding (yes)a ** 652 66.7 168 90.8 <0.001
Employment (yes) 539 54.8 112 60.5 0.1400
Drug  use
Ever sharing needle or syringe (yes)** 757 78.3 118 40.8 <0.001
Heroin use
Length (mean ± SD)** 6.9 ± 4.3 5.7 ± 5.2 <0.001
Age  of 1st use (mean ± SD) 25.9 ± 6.5 26.2 ± 6.8 0.5789
<25  (years old) 454 46.2 135 45.2 0.7532
≥25  (years old) 529 53.8 164 54.9
Injection as initial route** 400 40.7 110 60.1 <0.001
Injection as current route* 894 91.0 251 84.5 0.0016
Amphetamine (yes) 691 70.3 202 67.3 0.3290
Mean  age of 1st amphetamine use 23.4 ± 7.7 23 ± 7.6 0.5113
MDMA (yes) 64 6.5 17 5.7 0.5988
Mean  age of 1st MDMA use* 25.8 ± 7.5 21.2 ± 5.2 0.0186
Ketamine (yes) 103 10.5 22 7.3 0.1079
Mean  age of 1st ketamine use* 27.8 ± 7.2 23.7 ± 5.6 0.0145
Alcohol abuse/dependence (yes) 226 23.0 65 21.7 0.6317
Medical co-morbidity
HIV antibody positive** 176 18.1 18 6.3 <0.001
HCV  antibody positive* 885 91.4 146 86.4 0.0378
HBV  antigen positive 172 17.8 29 16.5 0.6788
Syphilis antibody positive 36 3.7 6 3.4 0.843
4
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va Bonding with family was determined by the status of living with family.
* p < 0.05.
** p < 0.001.
. Discussion
.1. Principal ﬁndings
Although previous studies have investigated the burden of
eroin use (Smyth et al., 2006; Degenhardt et al., 2013, 2014), this
tudy is the ﬁrst attempt to estimate both LE and EYLL among a
eroin user cohort. We  were also able to identify a subcohort who
id not attend OST during the 6-year observation period for com-
arison of the SMRs, LE, and EYLL between those with and without
ST. Despite lower education, less family bonding, higher propor-
ion of combined substances abuse, and higher prevalence rates of
o-morbid with HBV/HCV/HIV infections (Table 1), the OST group is
xpected to survive 7.8 years longer than that of the non-OST. The
ST group showed a substantially lower SMR  for overdose than was
he case for the non-OST group (Table 2), which also corroborates
he report by Davoli et al. (2007), thus reﬂecting the high validity
f this study. However, suicide mortality among OST group had a
vefold excess compared with that of non-OST group.
Our ﬁndings that the average EYLL was 10.6 and 18.4 for OST
nd non-OST heroin users, respectively, are compatible with a pre-
ious longitudinal cohort study tracked for over thirty-three yearsto contribute to a reduction in life expectancy of 14.65 years (Smyth
et al., 2006). Moreover, we  found that the average EYLL between
these two groups, which would be equivalent to LY saved by OST,
is 7.8 life-years (=18.4–10.6). Because the OST group showed higher
proportions of HIV and HCV infections and a lower proportion of
individuals with an elementary education than the non-OST group,
the former’s longer LE cannot be confounded by these factors. Thus,
this fact would be most likely related to OST treatment, and the ﬁg-
ures can be useful for arguing for the long-term ﬁnancial support
for OST.
4.2. Further validation of this study
We also calculated the cause-speciﬁc SMRs and compared the
results with the national cohort registered for OST  to validate the
representativeness of this sample. First, the all-cause mortality of
the OST group (Table 2) appears similar to the two nationwide
enrolled studies in Taiwan: one of them reported a one-year mor-
tality of 10,842 heroin users attending OST as 1.71% (Lee et al.,
2013), while the other showed annual mortality of 33,549 heroin
users attending OST as 1.35% (Liao et al., 2013). The SMR  for suicide
among the OST group in this study exhibited a 16.2-fold increase,
156 K.-C. Chang et al. / Drug and Alcohol Dependence 153 (2015) 152–158
Table 2
Estimated standardized mortality ratio (SMR) for heroin users cohort stratiﬁed by opioid substitution treatment (OST).
Causes OST group Non-OST group
Overall (person-years, PY) 4394.0 1425.0
Deaths (n) 68.0 34.0
Expected death (n) 9.1 3.3
SMR  7.5 (5.8–9.5) 10.2 (7.1–14.3)
Mortality rate (1000PY) 15.5 (11.8–19.2) 23.9 (15.8–31.9)
Cause-speciﬁc Deaths (n) SMR  95% CI Deaths (n) SMR 95% CI
Lower Upper Lower Upper
External 33 15.1 10.4 21.2 16 22.8 13.0 37.1
Accidents 16 14.6 8.3 23.8 15 41.6 23.2 68.8
Overdose 9 126.1 57.2 240.3 11 482.4 239.4 866.2
Suicide 17 16.2 9.4 26.0 1 3.1 0.0 17.6
Disease-related 35 5.1 3.6 7.1 18 6.9 4.1 10.9
Infectious disease 6 25.0 9.0 54.8 1 9.9 0.0 57.0
Mental disorder 1 11.4 0.0 65.4 0 – – –
Neoplasms 10 3.6 1.7 6.6 5 5.5 1.7 12.9
Liver  disease and hepatitis 4 4.1 1.1 10.5 1 3.4 0.0 19.2
Circulatory diseases 4 3.3 0.8 8.4 3 5.6 1.1 16.6
Respiratory diseases 1 3.2 0.0 18.3 1 4.5 0.0 25.9
Sudden/undeﬁned 7 13.6 5.4 28.2 4 20.8 5.41 53.77
ICD-9-CM codes: accidents: E800–E807, E820–E879, E930–E949, E970–E978, E980–E999, E810–E819, E880–E929; overdose: E850–E858, E980; suicide: E950–E959: homi-
cide:  E960–E969; infectious diseases: 001–139; mental disorder: 290–319; neoplasms: 140–239; liver disease and hepatitis: 570–573; circulatory diseases: 390–459;
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wespiratory diseases: 460–519; sudden/undeﬁned: 797–799. ICD-10-CM codes: acc
omicide: X85–Y09; infectious diseases: A00–B99; mental disorder: F00–F99; neo
espiratory diseases: J00–J99; sudden/undeﬁned: Y10–Y34, R00–R99. CI, conﬁdenc
hich is also similar to the estimated 18.4-fold increase found in
ee’s national cohort (Lee et al., 2013) and the 14-fold increase
ound in western countries (Darke and Ross, 2002). Moreover, the
haracteristics of our OST subjects (Table 1), including age, gen-
er, educational level, marital status, employment, the proportion
f injective use and HIV infection rate, were also similar to these
wo nationwide Taiwan studies, indicating a high degree of repre-
entativeness. Third, the excess mortality of the OST and non-OST
roups compared with the general population was consistent with
revious ﬁndings from western countries (Degenhardt et al., 2011).
argagli et al. (2005) also found signiﬁcant differences in many
haracteristics between those who came for methadone mainte-
ance treatment vs. who did not. As all heroin users who came
o our hospital were enrolled in this study, we believe that our
on-OST group would be representative to people with the same
ondition in southern part of Taiwan.
.3. Comparison of cause-speciﬁc mortality SMRs
We  must be cautious, however, because suicide-related SMR
as almost 16 times higher than in the general population among
he OST group, in comparison with 3 times that of the non-OST
roup (Table 2). One national sample study in a western country
eported that more than a quarter of the patients reported suicidal
houghts before treatment (Gossop et al., 1998), which was cor-
oborated by a study in Taiwan (Chen et al., 2010). In fact, another
aiwan study (Chen et al., 1999) showed that the prevalence of
ajor depressive disorder among treatment-seeking patients was
igniﬁcantly higher than that of untreated prisoners with opioid
ependence. Our ﬁnding complements the previous two ﬁndings
y providing a comparison of excess suicide mortality between
he treatment-seeking group (OST) and the non-OST group. From
ur insight understanding, 11 out of 17 suicide cases of OST group
eceived psychiatric treatment for depressive mood or symptoms
efore suicide. In addition, 6 out of 176 cases with HIV infection and
 additional cases with subsequent seroconversion to HIV commit-
ed suicides. Thus, as the prevalence rate of psychiatric disorder
as about 13% (Fan et al., 2013), the crude odds ratio would be: V01–X59, Y85–Y86; overdose: X40–X44; suicide: X60–X84, Y10–Y34 and Y87.0;
s: C00–D48; liver disease and hepatitis: K70–K77; circulatory diseases: I00–I99;
val.
about 13 times and they must be paid special attention on suicide
prevention.
Given that the prevalence rates of infection with HIV, hepati-
tis B and C, as well as alcohol use disorders, among OST subjects
were higher than those of non-OST, our estimations of differences of
overall SMR  (Table 2) and EYLL (Fig. 1) saved by OST would be con-
servative. Namely, the protective effect of OST could be even higher
than 7.8 life-years for EYLL. As Gibson et al. (2011) have pointed out
that the causes of deaths may  shift while heroin users age, we must
keep in mind to pay attention to the synergistic adverse impact of
heavy alcohol consumption among heroin users with HCV and/or
HBV infection in our long term provision of care.
4.4. Limitations
This study has following limitations: ﬁrst, nearly 18% of our OST
subjects were co-infected with HIV and HCV, which is signiﬁcantly
higher than that of the non-OST subjects. The reasons might be
that OST was initiated for an HIV epidemic among IDUs, and treat-
ment was  free for patients with HIV infection (Chen and Kuo, 2007).
Therefore, our results may  not be directly generalizable to other
heroin-abusing populations in western countries, for which the
EYLL saved by OST might be higher. Second, the lifetime extrap-
olation is based on current and prior experiences, including life
tables of the current population. We have not taken different lev-
els of OST adherence into account. Namely, the survival of heroin
addicts with a high level of adherence may  be longer than those
with a low level of adherence. Besides, the treatment technology
may improve in the coming years (Krupitsky et al., 2011; Rosenthal
et al., 2013). Therefore, our results may  underestimate the LE and
overestimate the EYLL for the OST treatment group. Third, it might
be possible that some of our non-OST subjects received other treat-
ment intervention such as self-paid buprenorphine elsewhere, but
such cases would be rare. Since methadone is a Schedule II con-
trolled drug and buprenorphine is a Schedule III controlled drug in
Taiwan, they are strictly regulated with heavy punishment, includ-
ing lifetime in prison by law. All clinics and hospitals are required
to provide all information on provision of such medication, and
any subject who  received publicly funded prescriptions of these
hol D
t
O
t
i
o
p
b
2
t
s
t
c
3
t
o
t
e
2
4
p
L
f
b
o
b
m
O
F
a
l
R
H
C
m
w
r
t
t
a
C
i
A
t
0
R
A
BK.-C. Chang et al. / Drug and Alco
wo medications would naturally be registered into the national
ST registry system. We  have deliberately linked every record of
he non-OST group with the national OST registry, in which we
dentiﬁed 326 subjects who were found later to have some record
f using either methadone or buprenorphine during the follow-up
eriod, and they were excluded from our non-OST group. Self-paid
uprenorphine treatment was permitted in Taiwan beginning in
010. But the medication is generally ﬁnancially heavy for long
erm maintenance. Among these subjects, if patients do not quickly
tabilize on buprenorphine (Kakko et al., 2007), they would be
emporarily transferred to methadone treatment and would be
aptured into the national OST registry. Therefore, the exclusion of
26 subjects from our non-OST groups would minimize such poten-
ial confounding. Fourth, this study has not considered the quality
f life into the ﬁnal outcome. Future studies adjusting survival func-
ion with quality of life are warranted for a more comprehensive
valuation (Hwang and Wang, 1999, 2004; Tsauo et al., 1999; Wang,
002).
.5. Conclusions
Despite higher suicide mortality compared with their counter-
arts, OST group have better survival and our ﬁndings showed that
Y saved by OST would be substantial, or, 7.8 years after adjustment
or lead time bias. The current estimate is probably conservative
ecause we have not stratiﬁed OST utilization into different levels
f adherence and because the OST group showed higher comor-
idities of HIV and HCV infections. Nonetheless, healthcare workers
ust pay special efforts on suicide prevention on subjects receiving
ST, especially among those co-morbid with depressive disorders.
uture studies should take into account quality of life, productivity
nd social cost to evaluate the overall impact of OST on a population
evel.
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